Full Press Release Details
Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive
Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
NEW YORK, October 11,
2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana"
or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of
drug delivery, today announced a late breaking poster titled, "Treatment Of Six Non-Active Secondary Progressive MS With Nasal
Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes", will be presented at the 39th Congress of
the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) being held in Milan, Italy, October 11-13, 2023.
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is a non-profit organization and an independent representative
European-wide organization devoted to multiple sclerosis (MS). It serves as Europe's and the world's largest professional
organization dedicated to the understanding and treatment of MS.
annual meeting of ECTRIMS is the world's largest MS research meeting. This year marks the 9th Joint ECTRIMS-ACTRIMS Meeting, which
takes place 11-13 October 2023 in Milan, Italy. the most relevant
issues facing MS and neurological experts today.
T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds
to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune
cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects.
The non-active SPMS intranasal foralumab Phase 2 trial is expected to start screening in November of 2023. Immunomodulation by nasal
anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.1,2
Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery
technologies to enable alternative routes of immunotherapy. Tiziana's innovative
nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV)
delivery. Tiziana's lead candidate, intranasal foralumab, which is the
only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response
in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications
pending and is expected to allow for broad pipeline applications.
Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
LifeSci Advisors, LLC